Alvotech is a multinational pharmaceutical company focused on the development and manufacture of biosimilars. We are driven by a vision to improve patient access to high-quality biologics worldwide. Our fully integrated approach, with end-to-end in-house capabilities, enables us to deliver high-quality biosimilars to patients around the world. Alvotech´s shares are traded on Nasdaq under the symbol ALVO.